Single-Enantiomer Drugs Poised for Further Market Growth

Although the therapeutic value of a given medicinal compound is the driving force behind development, a large number of currently marketed drugs and pipeline candidates are chiral, and pharmaceutical companies generally seek to develop these compounds as single-enantiomers. Single-enantiomer therape...

Full description

Saved in:
Bibliographic Details
Published in:Pharmaceutical Technology 2006-10, p.S14
Main Author: Erb, Sandra
Format: Magazinearticle
Language:English
Subjects:
Cancer
Competition
Drug dosages
Drug resistance
FDA approval
Generic drugs
Growth rate
Laboratories
Manufacturers
Manycompanies
Manyproducts
Medical research
Pharmaceutical industry
Pharmaceuticals
R&D
Regulatory approval
Research & development
Sales
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Although the therapeutic value of a given medicinal compound is the driving force behind development, a large number of currently marketed drugs and pipeline candidates are chiral, and pharmaceutical companies generally seek to develop these compounds as single-enantiomers. Single-enantiomer therapeutics had sales of $225 billion in 2005, representing 37% of the total final formulation pharmaceutical market of $602 billion, based on estimates from Technology Catalysts International and IMS Health. The compound annual growth rate for single-enantiomer products over the past five years is 11%, which is on par with the pharmaceutical market as a whole. The maturing of the single-enantiomer drug market is clearly seen by the arrival of generic competition. The angiotensin-converting enzyme inhibitors, the so-called "prils," are the first class of single-enantiomer compounds to face such competition. The following prils have had declining sales in the double-digit range: Pfizer's "Accupril" (quinapril); Novartis' "Lotensin" (benazepril); Bristol-Myers Squibb's "Monopril" (fosinopril); Merck & Co's "Vasotec" (enalapril); and AstraZeneca's "Zestril" (lisinopril).
ISSN:1543-2521
2150-7376